SK284341B6 - 2,7-Substituované oktahydro-1H-pyrido[1,2-a]pyrazínové deriváty a farmaceutické prostriedky na ich báze - Google Patents

2,7-Substituované oktahydro-1H-pyrido[1,2-a]pyrazínové deriváty a farmaceutické prostriedky na ich báze Download PDF

Info

Publication number
SK284341B6
SK284341B6 SK325-97A SK32597A SK284341B6 SK 284341 B6 SK284341 B6 SK 284341B6 SK 32597 A SK32597 A SK 32597A SK 284341 B6 SK284341 B6 SK 284341B6
Authority
SK
Slovakia
Prior art keywords
pyrido
octahydro
pyrazine
methyl
substituted
Prior art date
Application number
SK325-97A
Other languages
English (en)
Slovak (sk)
Other versions
SK32597A3 (en
Inventor
Kishor A. Desai
Anton F. J. Fliri
Mark A. Sanner
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of SK32597A3 publication Critical patent/SK32597A3/sk
Publication of SK284341B6 publication Critical patent/SK284341B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SK325-97A 1994-09-30 1995-08-24 2,7-Substituované oktahydro-1H-pyrido[1,2-a]pyrazínové deriváty a farmaceutické prostriedky na ich báze SK284341B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31547094A 1994-09-30 1994-09-30
PCT/IB1995/000689 WO1996010571A1 (fr) 1994-09-30 1995-08-24 Derives d'octahydro 1-h-pyrido[1,2-a] pyrazine substituee en 2,7

Publications (2)

Publication Number Publication Date
SK32597A3 SK32597A3 (en) 1998-09-09
SK284341B6 true SK284341B6 (sk) 2005-02-04

Family

ID=23224581

Family Applications (1)

Application Number Title Priority Date Filing Date
SK325-97A SK284341B6 (sk) 1994-09-30 1995-08-24 2,7-Substituované oktahydro-1H-pyrido[1,2-a]pyrazínové deriváty a farmaceutické prostriedky na ich báze

Country Status (34)

Country Link
US (1) US5852031A (fr)
EP (1) EP0783503B1 (fr)
JP (1) JP3287574B2 (fr)
KR (1) KR100244848B1 (fr)
CN (1) CN1068327C (fr)
AT (1) ATE209648T1 (fr)
AU (1) AU681310B2 (fr)
BR (1) BR9504230A (fr)
CA (1) CA2200959C (fr)
CO (1) CO4410335A1 (fr)
CZ (1) CZ285090B6 (fr)
DE (1) DE69524241T2 (fr)
DK (1) DK0783503T3 (fr)
ES (1) ES2166830T3 (fr)
FI (1) FI113655B (fr)
HR (1) HRP950507B1 (fr)
HU (1) HUT77354A (fr)
IL (1) IL115384A (fr)
MX (1) MX9702350A (fr)
MY (1) MY113729A (fr)
NO (1) NO308995B1 (fr)
NZ (1) NZ290936A (fr)
PE (1) PE47196A1 (fr)
PL (1) PL180899B1 (fr)
PT (1) PT783503E (fr)
RU (1) RU2163239C2 (fr)
SI (1) SI9520096A (fr)
SK (1) SK284341B6 (fr)
TR (1) TR199501194A2 (fr)
TW (1) TW406081B (fr)
UA (1) UA50720C2 (fr)
WO (1) WO1996010571A1 (fr)
YU (1) YU63795A (fr)
ZA (1) ZA958223B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6231833B1 (en) * 1999-08-05 2001-05-15 Pfizer Inc 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors
US6992188B1 (en) 1995-12-08 2006-01-31 Pfizer, Inc. Substituted heterocyclic derivatives
ATE205846T1 (de) * 1995-12-21 2001-10-15 Pfizer 2,7-substituierte octahydropyrrolo(1,2- a)pyrazinderivate
US6281216B1 (en) * 1998-02-09 2001-08-28 Duphar International Research B.V. 2-aminoquinoline derivatives having d4-agonistic activity
EP0953567A3 (fr) 1998-04-29 2003-04-02 Pfizer Products Inc. Dérivés de piperazin-, piperidine- et tetrahydropyridine bicyclique substitués, leur préparation et leur utilisation comme agents a activité dopaminergique (recepteur D4 de la dopamine) centrale
GT199900060A (es) * 1998-05-22 2000-10-14 Polimorfos de un monoclorhidrato de pirazina cristalino y sus composiciones farmacèuticas.
GB0010757D0 (en) 2000-05-05 2000-06-28 Astrazeneca Ab Chemical compounds
GB0011013D0 (en) * 2000-05-09 2000-06-28 Astrazeneca Ab Chemical compounds
EP1177792A3 (fr) 2000-07-27 2002-10-23 Pfizer Products Inc. Ligands dopamine d4 destines au traitement des troubles associees a la cherche de la nouveaute
US6670476B2 (en) 2000-11-29 2003-12-30 Pfizer Inc. Resolution of trans-7-(hydroxy-methyl)octa-hydro-2H-pyrido[1,2-a]pyrazine
GB0121941D0 (en) 2001-09-11 2001-10-31 Astrazeneca Ab Chemical compounds

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3388128A (en) * 1965-09-03 1968-06-11 Allan R. Day Substituted 1, 4-diazabicyclo [4. 4. 9] decanes
US4182763A (en) * 1978-05-22 1980-01-08 Mead Johnson & Company Buspirone anti-anxiety method
US4517187A (en) * 1982-10-18 1985-05-14 Pennwalt Corporation 1,3,4,6,7-11b-Hexahydro-7-phenyl-2H-pyrazino[2,1-a]isoquinolines methods of preparation, and use as antidepressants
EP0173634B1 (fr) * 1984-08-07 1988-08-31 Cortial S.A. Nouveaux dérivés d'(arylpipérazinyléthylaminoéthoxy)-4 phénol, leur méthode de préparation et leur application thérapeutique
US4704390A (en) * 1986-02-13 1987-11-03 Warner-Lambert Company Phenyl and heterocyclic tetrahydropyridyl alkoxy-benzheterocyclic compounds as antipsychotic agents
IT1204803B (it) * 1986-02-17 1989-03-10 Acraf Composto farmacologicamente attivo e composizioni farmaceutiche che lo contengono,procedimento per prepararlo e intermedio utile in detto procedimento
US4788290A (en) * 1987-12-11 1988-11-29 American Home Products Corporation Serotonergic pyrazine derivatives
SE8803429D0 (sv) * 1988-09-28 1988-09-28 Pharmacia Ab Novel pyridyl- and pyrimidyl derivatives
MX19222A (es) * 1989-01-23 1993-12-01 Pfizer Agentes ansioliticos bis-aza-biciclicos
EP0569387B1 (fr) * 1991-01-31 1995-04-05 Pfizer Inc. Decomposition de trans-2-(2-pyrimidinyle)-7-(hydroxymethyle)octahydro-2h-pyrido 1,2-a]pyrazine
US5157034A (en) * 1991-02-27 1992-10-20 Pfizer Inc. Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines
US5185449A (en) * 1991-02-27 1993-02-09 Pfizer Inc. Process and intermediate for certain bis-aza-bicyclic anxiolytic agents
ATE150453T1 (de) * 1991-02-27 1997-04-15 Pfizer Verfahren zur herstellung von trans-piperidin-2,5-dicarboxylaten
ES2096099T3 (es) * 1991-09-25 1997-03-01 Pfizer Perhidro-1h-pirido(1,2,a)pirazinas 2-sustituidas neurolepticas.
DK0646116T3 (da) * 1992-06-16 1999-12-27 Pfizer Fremgangsmåde og mellemprodukter til fremstilling af bis-aza-bicycliske anxiolytiske midler
WO1994010162A1 (fr) * 1992-10-23 1994-05-11 Merck Sharp & Dohme Limited Ligands pour les sous-types de recepteurs de dopamine
AU678186B2 (en) * 1992-10-23 1997-05-22 Merck Sharp & Dohme Limited Dopamine receptor subtype ligands
WO1994020497A1 (fr) * 1993-03-01 1994-09-15 Merck Sharp & Dohme Limited Derives de pyrrolo-pyridine
US5576319A (en) * 1993-03-01 1996-11-19 Merck, Sharp & Dohme Ltd. Pyrrolo-pyridine derivatives
AU679040B2 (en) * 1993-03-01 1997-06-19 Merck Sharp & Dohme Limited Pyrrolo-pyridine derivatives as dopamine receptor ligands
JPH08508466A (ja) * 1993-03-05 1996-09-10 メルク シヤープ エンド ドーム リミテツド ドーパミンｄ４リガンドとしてのキノロン誘導体
GB9416162D0 (en) * 1994-08-10 1994-09-28 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
SI9520096A (sl) 1998-04-30
EP0783503A1 (fr) 1997-07-16
WO1996010571A1 (fr) 1996-04-11
DE69524241T2 (de) 2002-06-13
KR970706282A (ko) 1997-11-03
PL180899B1 (pl) 2001-04-30
JPH09511527A (ja) 1997-11-18
ZA958223B (en) 1997-04-01
UA50720C2 (uk) 2002-11-15
ES2166830T3 (es) 2002-05-01
DE69524241D1 (de) 2002-01-10
RU2163239C2 (ru) 2001-02-20
MX9702350A (es) 1997-06-28
MY113729A (en) 2002-05-31
AU681310B2 (en) 1997-08-21
TR199501194A2 (tr) 1996-06-21
PE47196A1 (es) 1996-11-11
CA2200959C (fr) 2000-05-23
CZ285090B6 (cs) 1999-05-12
JP3287574B2 (ja) 2002-06-04
HRP950507A2 (en) 1997-08-31
HRP950507B1 (en) 2002-06-30
DK0783503T3 (da) 2002-02-11
CA2200959A1 (fr) 1996-04-11
AU3189395A (en) 1996-04-26
EP0783503B1 (fr) 2001-11-28
NO308995B1 (no) 2000-11-27
US5852031A (en) 1998-12-22
PT783503E (pt) 2002-03-28
YU63795A (sh) 1999-03-04
BR9504230A (pt) 1996-08-06
TW406081B (en) 2000-09-21
SK32597A3 (en) 1998-09-09
CN1168672A (zh) 1997-12-24
FI971310A0 (fi) 1997-03-27
FI113655B (fi) 2004-05-31
IL115384A0 (en) 1995-12-31
NZ290936A (en) 1998-01-26
CN1068327C (zh) 2001-07-11
KR100244848B1 (ko) 2000-03-02
IL115384A (en) 1999-10-28
PL319636A1 (en) 1997-08-18
CO4410335A1 (es) 1997-01-09
NO971416L (no) 1997-05-20
FI971310A (fi) 1997-03-27
CZ94797A3 (cs) 1998-07-15
HUT77354A (hu) 1998-03-30
NO971416D0 (no) 1997-03-25
ATE209648T1 (de) 2001-12-15

Similar Documents

Publication Publication Date Title
AU2021295423B2 (en) Quinoxaline derivatives as anti-cancer drugs
CN112752757B (zh) 作为rho-激酶抑制剂的酪氨酸酰胺衍生物
AU775093B2 (en) 2,7-substituted octahydro-1H-pyrido(1,2-a)pyrazine derivatives as ligands for serotonin receptors
SK284341B6 (sk) 2,7-Substituované oktahydro-1H-pyrido[1,2-a]pyrazínové deriváty a farmaceutické prostriedky na ich báze
CN113773335A (zh) 一种作为蛋白质激酶抑制剂的化合物及其制备方法和用途
RU2162470C2 (ru) 2,7-замещенные производные октагидропирроло[1,2-а]пиразина, способ лечения, фармацевтическая композиция, промежуточные соединения
TW202321232A (zh) 小分子sting拮抗劑
MXPA00006403A (en) 2,7-substituted octahydro-1h-pyrido[1,2-a]pyrazine derivatives